Elicio Therapeutics ELTX 深 沪
交易中 10-14 10:52:54 美东时间
1.905
+0.135
+7.63%
华盛通- 最 高1.9101
- 今 开1.77
- 成交量 14.67万股
- 最 低 1.75
- 昨 收 1.77
- 总市值 5160.87万
- 52周最高 16.00
- 市盈率 静 --
- 换手率 0.54%
- 52周最低 1.705
- 委 比 -93.55%
- 总股本 2709.12万
- 历史最高 263.00
- 量 比 3.85
- 振 幅 9.05%
- 历史最低 1.705
- 每 手 1
- 风险率 3.63%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Meta获4家机构齐升目标价，最高看至995美元！麦当劳遭6家机构下调，最低看至260美元
今日重点评级关注：Canaccord Genuity：维持Aurora Innovation"买入"评级，目标价从15美元升至17美元；摩根大通：维持皇家加勒比邮轮"超配"评级，目标价从345美元升至394美元
09-25 15:55
B. Riley Securities Maintains Buy on Elicio Therapeutics, Lowers Price Target to $8
B. Riley Securities analyst Mayank Mamtani maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and lowers the price target from $27 to $8.
09-24 22:16
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
Elicio Therapeutics announced new pre-specified analyses from its Phase 2 AMPLIFY-7P study of ELI-002 7P in pancreatic ductal adenocarcinoma (PDAC), to be presented as a late-breaking Proffered Paper at the ESMO Congress 2026 in Madrid. The findings aim to refine the Phase 3 development strategy for adjuvant pancreatic cancer treatment. Despite not meeting the primary disease-free survival endpoint, the study provided insights into ELI-002 7P's c...
09-24 12:00
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
Elicio Therapeutics, a clinical-stage biotech company developing immunotherapies for KRAS-driven cancers, announced that its management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026, in Boston. The company focuses on off-the-shelf immunotherapy candidates targeting common cancer mutations, including KRAS, BRAF, and p53, aiming for rapid manufacturing and patient access. For more...
08-24 12:00
美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $23 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Elicio Therapeutics (NASDAQ:ELTX) with a Buy and maintains $23 price target.
08-18 19:27
Elicio Therapeutics Q2 EPS $(0.43) Beats $(0.54) Estimate
Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.54) by 20.37 percent. This is a 34.85 percent increase over losses of $(0.66) per share from the same period last year.
08-14 04:18
11 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's regular session. The market value of their outstanding shares is at $12.2 million. Liminatus Pharma (NASDAQ:LIMN) shares rose 26.04% to $0.14. The market value of their outstanding shares is at $5.8 milli...
07-03 01:05
Ladenburg Thalmann Assumes Elicio Therapeutics at Buy, Announces Price Target of $12
Ladenburg Thalmann analyst Kevin DeGeeter assumes Elicio Therapeutics (NASDAQ:ELTX) with a Buy rating and announces Price Target of $12.
06-19 03:03
美股夜盘 | Linkers Industries Limited Class A涨40.63%，Rumble涨17.42%
Sleep Number Corporation涨-31.44%；Elicio Therapeutics, Inc涨-19.11%；君长数码涨-13.15%
06-18 08:05
